Details for Patent: 6,503,911

✉ Email this page to a colleague

Summary for Patent: 6,503,911

Title:	Sustained release ranolazine formulations
Abstract:	A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
Inventor(s):	Wolff; Andrew A. (San Francisco, CA), Baker; Fiona (Dunfermline, GB), Langridge; John (Wrexham, GB)
Assignee:	CV Therapeutics, Inc. (Palo Alto, CA) Syntex USA, Inc. (Palo Alto, CA)
Application Number:	10/041,521
Patent Claim Types: see list of patent claims	Composition; Dosage form;

Drugs Protected by US Patent 6,503,911

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 6,503,911

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1109558	⤷ Sign Up	PA2008017	Lithuania	⤷ Sign Up
European Patent Office	1109558	⤷ Sign Up	CA 2008 00051	Denmark	⤷ Sign Up
European Patent Office	1109558	⤷ Sign Up	91504	Luxembourg	⤷ Sign Up
European Patent Office	1109558	⤷ Sign Up	PA2008017,C1109558	Lithuania	⤷ Sign Up
European Patent Office	1109558	⤷ Sign Up	09C0001	France	⤷ Sign Up
European Patent Office	1109558	⤷ Sign Up	SPC/GB08/058	United Kingdom	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.